Our Platform
RIS Rx’s pharmacist-led platform prevents GTN revenue leakage in real time across payers, pharmacies, and AFPs to protect revenue and reduce copay misuse.

RIS Rx is a real-time GTN revenue protection platform for pharmaceutical manufacturers.
risrx.comCrawled Nov 2, 2026
RIS Rx’s pharmacist-led platform prevents GTN revenue leakage in real time across payers, pharmacies, and AFPs to protect revenue and reduce copay misuse.
Gerard Rivera shows why patient affordability programs are life-saving, not optional, and how they protect care continuity when insurance falls short.
RIS Rx Benefit Patient Solution (BPS) helps pharmacies and providers spot affordability gaps in real time, reducing copay walkaways and wasted copay assistance.
Why RIS Rx was built: fix copay card blind spots, cut revenue leakage, and help pharma teams keep patients on therapy with real-time insight.
RIS Rx reflects on a year of change, new partners, team growth, and patient-first values driving progress on drug affordability and the people behind it.
RIS Rx Insights, updates, and guidance on GTN revenue protection, PBM leakage, and affordability programs, with email sign-up and demos for pharma teams.
RIS Rx explains the $90B gross-to-net leakage behind pharmacy counter walkaways and misused support dollars, and how real-time recovery helps patients.
GTN Revenue Protection platform highlights industry focus on protecting patient affordability and improving visibility across the Gross-to-Net ecosystem.
John Driscoll was appointed Chairman of the RIS Rx Board of Directors.
RIS Rx offers a platform to support patient affordability in healthcare.
RIS Rx was built by pharmacists to protect patients in need, improve affordability, reduce copay surprises, and keep copay dollars reaching patients.
RIS Rx provides real-time GTN Revenue Protection and is located at 5300 California Ave, Suite 300, Irvine, CA 92617.
RIS Rx’s GTN Revenue Protection platform addresses revenue leakage and copay misuse for pharmaceutical companies.
Led by pharmacists, RIS Rx provides real-time gross-to-net (GTN) revenue protection for pharma, delivering $1B+ in annual savings and supporting 3M+ patients.
Terms of Use for RIS Rx include trademarks, copyrights, disclaimers, and site terms governing website use for customers, partners, and visitors.
RIS Rx introduces real-time monitoring to its Triple A platform, identifying misprocessed pharmacy claims during transactions. Pharmacists at RIS Rx review and resolve each flagged claim through direct PharmD-to-PharmD engagement, ensuring corrections before claims are finalized.
RIS Rx launches **GTN Revenue Protection**, a new brand platform aimed at safeguarding patient affordability investments. The move aligns with rising industry emphasis on enhancing visibility and efficiency within the Gross-to-Net (GTN) revenue cycle. The platform targets stakeholders managing financial and operational complexities in healthcare revenue management.
RIS Rx appoints Leslie Donato to its Board of Directors. The company expands its leadership team with Donato’s addition, though no specific role or background details are provided in the announcement.
RIS Rx adds Stuart McGuigan to its Board of Directors. The company specializes in digital health solutions for pharmacy and healthcare providers. McGuigan brings executive experience in technology and healthcare sectors.
RIS Rx appoints John Driscoll as Chairman of its Board of Directors. Driscoll brings leadership experience to guide the company’s strategic direction. The announcement highlights the organization’s commitment to strengthening its governance structure.
RIS Rx secures a growth investment from **Summit Partners** to expand its healthcare technology solutions targeting **pharmacy fraud and gross-to-net (GTN) revenue leakage**. The company focuses on reducing financial losses in pharmaceutical pricing while improving patient access to treatments. The funding will accelerate innovation and operational growth in its specialized revenue-protection services.